Abstract To evaluate the efficacy of salvage radiochemotherapy (SRC) in patients with recurrent lymph node after radical surgery in esophageal cancer. This study enrolled 58 patients with esophageal squamous cell carcinoma who underwent SRC for lymph node recurrence after radical surgery from August 2011 to November 2015 at our hospital. Survival rates were calculated by the Kaplan–Meier method with the log-rank test. Multivariate analysis was conducted using the Cox model. The overall 1-, 3-, and 5-year survival rates after radical surgery were 94.8%, 53.0%, and 29.6%, respectively. The 1- and 3-year survival rates after SRC were 68.7% and 26.9%, respectively. The major acute toxicities were esophagitis and neutropenia, while most toxicities were grade 1 or 2. There was no unexpected increase in serious adverse events or treatment-related deaths. The results of multivariate analysis showed that time to recurrence (odds ratio [OR]: 0.25, 95% confidence interval [CI]: 0.11–0.53, P = .0004), T stage (OR: 2.75, 95%CI: 1.16–6.49, P = .021), and prophylactic radiotherapy/chemotherapy (PRC, OR: 0.39, 95%CI: 0.16–0.98, P = .045) were determinants of postoperative overall survival, and PRC was the only factor affecting the outcome of SRC (OR: 0.28, 95%CI: 0.12–0.70, P = .006). SRC is an effective treatment for recurrent lymph node after radical surgery of esophageal cancer.

中文翻译：

---

食管癌根治术后淋巴结复发的挽救性放化疗

摘要 评价挽救性放化疗（SRC）对食管癌根治术后淋巴结复发患者的疗效。本研究纳入了2011年8月至2015年11月在我院接受根治术后淋巴结复发行SRC的58例食管鳞癌患者。存活率通过 Kaplan-Meier 方法和对数秩检验计算。使用 Cox 模型进行多变量分析。根治性手术后的总体 1、3 和 5 年生存率分别为 94.8%、53.0% 和 29.6%。SRC 术后 1 年和 3 年生存率分别为 68.7% 和 26.9%。主要的急性毒性是食管炎和中性粒细胞减少症，而大多数毒性为 1 级或 2 级。严重不良事件或治疗相关死亡没有意外增加。多变量分析结果显示复发时间（比值比 [OR]：0.25，95% 置信区间 [CI]：0.11-0.53，P = .0004），T 分期（OR：2.75，95%CI：1.16- 6.49，P = .021）和预防性放疗/化疗（PRC，OR：0.39，95%CI：0.16-0.98，P = .045）是术后总生存率的决定因素，PRC是影响预后的唯一因素SRC（OR：0.28，95% CI：0.12–0.70，P = .006）。SRC是食管癌根治术后淋巴结复发的有效治疗方法。045) 是术后总生存率的决定因素，PRC 是影响 SRC 结果的唯一因素 (OR: 0.28, 95% CI: 0.12–0.70, P = .006)。SRC是食管癌根治术后淋巴结复发的有效治疗方法。045) 是术后总生存率的决定因素，PRC 是影响 SRC 结果的唯一因素 (OR: 0.28, 95% CI: 0.12–0.70, P = .006)。SRC是食管癌根治术后淋巴结复发的有效治疗方法。